Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
2.290
+0.060 (2.69%)
May 7, 2026, 4:00 PM EDT - Market closed
CELZ Revenue
In the year 2025, Creative Medical Technology Holdings had annual revenue of $6.00K, down -45.45%. Creative Medical Technology Holdings had revenue of $3.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$6.00K
Revenue Growth
-45.45%
P/S Ratio
1,410.90
Revenue / Employee
$1,500
Employees
4
Market Cap
8.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.00K | -5.00K | -45.45% |
| Dec 31, 2024 | 11.00K | 2.00K | 22.22% |
| Dec 31, 2023 | 9.00K | -79.60K | -89.84% |
| Dec 31, 2022 | 88.60K | 846.00 | 0.96% |
| Dec 31, 2021 | 87.75K | -76.75K | -46.65% |
| Dec 31, 2020 | 164.50K | -1.00K | -0.60% |
| Dec 31, 2019 | 165.50K | 41.10K | 33.04% |
| Dec 31, 2018 | 124.40K | 119.60K | 2,491.67% |
| Dec 31, 2017 | 4.80K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 7.70M |
| Evogene | 3.85M |
| BioAtla | 2.00M |
| XTL Biopharmaceuticals | 968.00K |
| Can-Fite BioPharma | 405.00K |
CELZ News
- 9 days ago - Creative Medical knee data ‘highly positive,’ says Roth Capital - TheFly
- 9 days ago - Creative Medical reports pilot study of Ultrasome meets priamry endpoint - TheFly
- 9 days ago - Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies - GlobeNewsWire
- 3 months ago - Creative Medical achieves second WHO INN milestone - TheFly
- 4 months ago - Creative Medical announces interim data from ADAPT trial of CELZ-201 - TheFly
- 4 months ago - Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain - GlobeNewsWire
- 4 months ago - Creative Medical receives regulatory approval for BioDefense Burn Pit Initiative - TheFly
- 4 months ago - Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative - GlobeNewsWire